Standard Curve
Example of Human G-CSF standard curve in Assay Diluent VA11. Plotted are the background-subtracted data.
This standard curve is provided for demonstration only.
Product Details
Product Details
Product Specification
| Antigen | G-CSF |
| Immunogen | Recombinant Protein |
| Antibody Type | Recombinant mAb |
| Reactivity | Hu |
| Purification | Protein A |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8°C as supplied. |
Kit
| Precision | Intra-assay: 3.2%; Inter-assay: 3.5% |
| Sample type | Serum; EDTA Plasma, Citrate Plasma |
| Assay type | Sandwich (quantitative) |
| Sensitivity | 0.118 ng/mL |
| Range | 0.3 ng/mL – 20 ng/mL |
| Recovery | Serum: 99.3% EDTA Plasma: 87.0% Citrate plasma: 84.3% |
| Assay time | 60 minutes |
| Species reactivity | Hu |
Background
Human Granulocyte Colony-Stimulating Factor (G-CSF) is a ~20 kDa glycoprotein of 174 amino acids that functions as the principal hematopoietic cytokine controlling neutrophil production and function. It is produced mainly by endothelial cells, monocytes-macrophages, and fibroblasts upon stimulation such as infection, and it drives the proliferation, survival, and neutrophilic differentiation of myeloid progenitor cells by activating its specific receptor. This receptor belongs to the hematopoietin receptor superfamily and triggers multiple signaling cascades that balance steady-state and "emergency" granulopoiesis. G-CSF deficiency in mice leads to neutropenia, reduced hematopoietic progenitors, and increased susceptibility to spontaneous infections. Clinically, recombinant human G-CSF is widely used to treat congenital and acquired neutropenias, reduce infectious complications during chemotherapy, and enable dose-intensified cancer treatment. More recent evidence also suggests potential therapeutic applications beyond neutropenia, including cardiac and brain infarction. Thus, human G-CSF serves as both a critical physiological regulator of innate immunity and an essential clinical tool in hematology and oncology.
Picture
Picture
ELISA
Spike Recovery
The recovery of Human G-CSF was evaluated in activated samples spiked with concentrations spanning the entire assay range.
Spike-and-dilution Linearity
To evaluate assay linearity, three samples were spiked with high levels of Human G-CSF in different matrices and serially diluted with the corresponding Calibrator Diluent to fall within the assay's dynamic range.
Intra-Assay Precision (Precision within an assay)
Three samples of known concentration were tested fifteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays).
Three samples of known concentration were tested in separate assays to assess inter-assay precision. Assays were performed with at least three lots of components.
Determination of Minimum Detectable Dose (MDD)
The MDD was determined using three independent lots of assay components. For each lot, 19 replicate measurements of the diluent (zero calibrator) were performed. The mean (AVERAGE) and standard deviation (STDEV) of the 19 replicates were calculated. The MDD for each lot was then calculated according to the following formula:
MDD = 2 × STDEV + AVERAGE
Protocol Diagram
